Growth Hormone Peptides and Fat Loss: Tesamorelin, Ipamorelin, CJC-1295, AOD-9604

Growth hormone raises lipolysis, which is why the GH axis was an obvious fat-loss target and why a family of peptides was built to poke at it. Four of them dominate clinic menus and vendor pages. Exactly one, tesamorelin, holds an FDA approval, and that approval covers visceral fat in adults with HIV and lipodystrophy rather than weight loss. Another, AOD-9604, failed a 536-subject phase 2b trial and was abandoned in 2007, and is still sold for fat loss today. Here is what is known for each.

The GH axis, and why it looked like a fat-loss target

Growth hormone increases the breakdown of stored fat and shifts body composition toward lean mass. Giving people recombinant GH directly produces those effects along with glucose intolerance, fluid retention and joint pain, so the pharmacological idea was to nudge the body's own GH release rather than replace it.

Two approaches emerged. GHRH analogues such as tesamorelin and CJC-1295 mimic the hypothalamic signal that tells the pituitary to release GH. Ghrelin-receptor agonists such as ipamorelin work through a separate secretagogue pathway. AOD-9604 is a different idea again, a fragment of the GH molecule meant to isolate its fat-burning activity. The mechanism reasoning is sound, and sound mechanism reasoning is where drug development starts.

Tesamorelin: approved, for something specific

Tesamorelin, sold as Egrifta, is a growth hormone releasing factor analogue given by daily injection. FDA approved it on 10 November 2010 to induce and maintain reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. A concentrated F8 formulation, EGRIFTA WR, was subsequently approved for the same indication.

Read that indication closely. It names a clinical population, HIV-associated lipodystrophy, and a specific fat compartment, visceral abdominal fat. It is not an approval for obesity and not an approval for general weight loss, and the drug was not studied as a treatment for either. Presenting its label effect as a weight-loss result misrepresents what the trials measured. Because it raises endogenous GH, the GH-axis effects apply: glucose intolerance, fluid retention, arthralgia, and the contraindications listed on the label. Use for general fat loss is off-label.

Ipamorelin and CJC-1295

Neither is FDA-approved. Neither has been evaluated by FDA for the diagnosis, treatment, cure or prevention of any disease. That is a stronger statement than not approved yet, because it means the agency has not assessed them for a medical use at all.

Human clinical evidence for either compound is limited in scale and scope, and evidence for the combination, which is how they are usually sold, is thinner still. There is no adequate controlled weight-loss trial for either one. Claims of fat reduction in clinic marketing rest on mechanism plus small studies plus testimonial, not on a trial that measured weight loss against placebo.

Stacking them produces a larger GH pulse than either alone, which raises the unknowns rather than settling them. Both were on the FDA 503A Category 2 peptide review track along with other secretagogues, and the regulatory position for peptide compounding shifted during 2026, so it should be re-checked against FDA directly before a compounding pharmacy's willingness to supply is read as evidence of legality.

AOD-9604: the trial that failed

AOD-9604 is a synthetic fragment of human growth hormone, residues 176 to 191. An early 12-week trial showed 2.6 kg weight loss against 0.8 kg on placebo, which was encouraging enough to justify a larger study.

The larger study settled it. A 24-week phase 2b trial in 536 subjects failed to induce significant weight loss and did not separate from placebo at any dose. Development as a drug candidate was abandoned in 2007, and reviews of the human data conclude there is no clinically significant fat loss versus placebo. AOD-9604 holds no regulatory approval from any major health authority, is marketed through wellness and compounding channels regardless, and appears on fat-loss peptide lists nearly twenty years after its own pivotal trial said no.

How this market cites its evidence

The AOD-9604 case is the clearest example of a pattern that runs through GH-peptide marketing. A real dataset exists. It is quoted accurately. It is the wrong dataset for the claim being made.

Watch for the substitutions. Safety data standing in for efficacy data, as above. Preclinical data written so the species disappears, where reduced adiposity means mice. Mechanism standing in for outcome, where a compound raises GH, GH is lipolytic, and no trial in the chain measured fat loss in people.

One question cuts through it: which trial, in humans, measured body weight or fat mass against placebo, and what did it find? For tesamorelin the answer exists in a narrow population. For AOD-9604 it exists and is negative. For ipamorelin and CJC-1295 there is no adequate answer.

The evidence, one row per claim

Sources

1. FDA EGRIFTA SV prescribing information
2. Infectious Disease Advisor
3. Innerbody
4. Evidence review (verify against the primary trial publication before publishing)
5. PepCodex evidence review (secondary)
6. Secondary guide

Keep reading

• Peptides for Weight Loss: A Tiered Guide to What Is Approved, Pipeline, and Grey MarketThe triage page. Place any compound name into one of three tiers in seconds, with the best trial number and th
• Research-Chemical Peptides: 5-Amino-1MQ and the Grey MarketThe consumer-protection page, built around the cleanest example of a compound with everything except human evi
• BPC-157: What It Is, What It Is Not, and Its Unsettled Legal StatusA corrective page. The evidence base is tissue repair, the weight-loss listings are a marketing artefact, and